Other studies have found that PD-1/L1 inhibitors can significantly reduce the viability of H1975 cells in vitro that are resistant to gefitinib, suggesting that combined immunotherapy with TKI may be an alternative for the treatment of patients with EGFR mutation in NSCLC, especially those who are resistant to EGFR-TKI [96]. Here, PDCD1 is linked to non-small cell lung carcinoma.